We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Accelerating Antibody Discovery With Advanced Label-Free Technology

antibody discovery

The development of antibodies for diagnostics or therapeutics requires comprehensive characterization of affinity, specificity and mechanism of action. In particular, antibody-drug conjugates (ADCs) are an exciting and emerging class of biopharmaceuticals with applications in cancer. 

Biolayer Interferometry (BLI) is a label free technique that is widely used for the quantitation of antibodies, which is fundamental to biological research and production processes. The technology is also extensively used for kinetics measurements of antibodies and small molecules to assess the strength and speed of binding of an antibody to a target.

This eBook explores advances in biosensor technology and instrumentation that can significantly accelerate antibody discovery through efficient quantitation, kinetics and epitope binning. 

Download this eBook to learn more about :

  • How to overcome ADC manufacturing challenges 
  • Multi-specific Ab analytical strategies
  • Advances in BLI biosensors for robust antibody quantitation
Sponsored by

Access Your eBook for FREE Below
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.